|Diplomat Dispensing MAVYRET(TM) to Treat Chronic Hepatitis C|
|By: PR Newswire Association LLC. - 17 Aug 2017||Back to overview list
FLINT, Mich., Aug. 17, 2017 /PRNewswire/ -- Diplomat Pharmacy, Inc. (NYSE: DPLO), is dispensing newly approved MAVYRET™ (glecaprevir and pibrentasvir) oral tablets for chronic hepatitis C virus infection.
To learn more about Diplomat's hepatitis program, visit diplomat.is/areas-of-excellence/hepatitis.
MAVYRET is indicated for patients with all major genotypes (1–6) of chronic hepatitis C virus infection without cirrhosis (liver disease) or with compensated cirrhosis. It is the first eight-week treatment duration approved for all genotypes in adult patients without cirrhosis who have not been previously treated.
MAVYRET is also indicated for adults with Genotype 1 infection who previously have been treated with a regimen containing an NS5A inhibitor or an NS3/4A protease inhibitor (but not both).
"We are proud to expand upon Diplomat's therapy offerings to patients who have been diagnosed with chronic hepatitis C," said Joel Saban, president of Diplomat. "This valuable treatment option gives more patients the possibility of a life without this serious disease."
More than 2.7 million Americans have hepatitis C, according to the Centers for Disease Control and Prevention. Hepatitis C infection becomes chronic in approximately 75–85 percent of cases.
MAVYRET is manufactured by AbbVie Inc. For full prescribing information, click here.
Gary Rice, RPh, MS, MBA, CSP
View original content with multimedia:http://www.prnewswire.com/news-releases/diplomat-dispensing-mavyret-to-treat-chronic-hepatitis-c-300506166.html
SOURCE Diplomat Pharmacy, Inc.
Copyright 2017 PR Newswire Association LLC.
|Back to overview list|